Traws Pharma (TRAW) Intangibles (2025 - 2026)
Traws Pharma (TRAW) posted quarterly Intangibles of $2.6 million for Q1 2026, up 2.3% quarter-over-quarter from $2.5 million in Q4 2025.
Traws Pharma (TRAW) Intangibles (2025 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Intangibles for 2 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles changed N/A year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (changed N/A YoY), while the FY2025 annual figure was $2.5 million, changed N/A from the prior year.
- Intangibles grew to $2.6 million in Q1 2026 per TRAW's latest filing, from $2.5 million in the prior quarter.
- Across five years, Intangibles topped out at $2.6 million in Q3 2025 and bottomed at $2.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Traws Pharma | 5.66 Mn | 639,491.99 | - | 2.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.59 Mn |
| Dec 31, 2025 | 2.53 Mn |
| Sep 30, 2025 | 2.59 Mn |